Relative biological effectiveness of low-energy X-rays (25 kV) in mutant p53 cancer cells

Radiat Environ Biophys. 2023 Mar;62(1):161-170. doi: 10.1007/s00411-022-01014-z. Epub 2023 Jan 7.

Abstract

Low-energy X-rays as used in radiation therapy and diagnostics such as mammography are associated with a certain risk of promoting tumour development, especially in patients with mutations in cancer-related genes like TP53. The present study therefore addressed the relative biological effectiveness (RBE) of low-energy X-rays for two human adenocarcinoma cell lines of the breast (MDA-MB-468) and pancreas (BxPC-3) with a mutation in the TP53 gene. Clonogenic survival and cytogenetic changes in terms of micronuclei (MN) formation were determined following irradiation with 25 kV X-rays and 200 kV reference irradiation in the dose range of 1-8 Gy. Except the frequency of MN-containing binucleated cells (BNC) (BNC + MN/BNC) in breast cancer cells yielding an RBE between 0.6 and 0.8, both cell lines displayed dose-dependent variations of RBE values between 1 and 2 for all biological end points (cell survival, (BNC + MN/BNC), MN/BNC, MN/(BNC + MN)) with increased effectiveness of 25 kV irradiation in pancreatic compared to breast cancer cells. The results confirm previous findings indicating increased effectiveness of low-energy X-rays and underline the necessity of careful risk estimation for cancer screening programmes.

Keywords: Breast cancer; Mammography; Pancreatic cancer; RBE; Soft X-rays; p53.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms* / genetics
  • Breast Neoplasms* / radiotherapy
  • Dose-Response Relationship, Radiation
  • Female
  • Genes, p53*
  • Humans
  • Relative Biological Effectiveness
  • Tumor Suppressor Protein p53 / genetics
  • X-Rays

Substances

  • Tumor Suppressor Protein p53
  • TP53 protein, human